Join to View Full Profile
3400 Civic Center Blvd2 WestPhiladelphia, PA 19104
Phone+1 215-615-5121
Dr. Marmarelis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Melina Marmarelis is an oncologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center. She received her medical degree from Harvard Medical School and has been in practice 4 years. She is experienced in lung cancer and medical education.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2016 - 2019
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2013 - 2016
Harvard Medical SchoolClass of 2013
Certifications & Licensure
PA State Medical License 2016 - 2026
MA State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resou...Mariam Alexander, Ying Cheng, Se-Hoon Lee, Antonio Passaro, Alexander I Spira
European Journal of Cancer. 2025-09-09 - Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced N...Omar Elghawy, Adam Barsouk, Jonathan H Sussman, Benjamin A Bleiberg, Lauren Reed-Guy
JTO Clinical and Research Reports. 2025-09-01 - Immunotherapy for Resectable Non-Small Cell Lung Cancer-Not If, But When.Lauren Reed-Guy, Melina E Marmarelis
JAMA Network Open. 2025-06-02
Press Mentions
What's 'Neo' in Treatment Options for Resectable NSCLC?August 8th, 2025- In Early NSCLC, Molecular Testing Rates Improve with EMR NudgeMay 28th, 2025
- Genomic Profile Availability Impact on NSCLC Patient Outcomes in Real World Study and Daily PracticeAugust 22nd, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
